How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 2, 2017, Pages 139-149

  Beeh, Kai M ^a   Burgel, Pierre Regis ^b   Franssen, Frits M E ^c   Lopez Campos, Jose Luis ^d,e   Loukides, Stelios ^f   Hurst, John R ^g   Fležar, Matjaž ^h   Ulrik, Charlotte Suppli ⁱ   Marco, Fabiano Di ^j   Stolz, Daiana ^k   Valipour, Arschang ^l   Casserly, Brian ^m,n   Ställberg, Björn ^o   Kostikas, Konstantinos ^p   Wedzicha, Jadwiga A ^q  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b Institut Cochin   (France)

^c Centre of Expertise for Chronic Organ Failure   (Netherlands)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY OF ATHENS   (Greece)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^m UNIVERSITY HOSPITAL LIMERICK   (Ireland)

ⁿ UNIVERSITY OF LIMERICK   (Ireland)

^o UPPSALA UNIVERSITY   (Sweden)

^p NOVARTIS PHARMA AG   (Switzerland)

^q NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

Hyperinflation; Inflammation; Inhaled corticosteroid; Mucus

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; HYPERINFLATION; MECHANICAL STRESS; METHODOLOGY; MUCOCILIARY CLEARANCE; MUCUS SECRETION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYMPTOM; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85025154852     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201609-1794CI     Document Type: Review

References (118)

1. Wedzicha JA, Seemungal TA. COPD exacerbations: Defining their cause and prevention. Lancet 2007;370:786-796.
2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
3. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-1097.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
5. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009;4:245-251.
6. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-452.
7. Bourbeau J. Activities of life: The COPD patient. COPD 2009;6:192-200.
8. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: Severe exacerbations and mortality. Thorax 2012;67:957-963.
9. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease; 2016 [updated 2015; accessed 2016 Jun 20]. Available from: Http://goldcopd.org/global-strategy-diagnosis-management-preventioncopd-2016/
11. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, SarosiGA, Krumpe P, PieperK, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-28.
12. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, Roche N; Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-982.
13. Wan ES, DeMeo DL, Hersh CP, Shapiro SD, Rosiello RA, Sama SR, Fuhlbrigge AL, Foreman MG, Silverman EK. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med 2011;105:588-594.
14. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
15. O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61:354-361.
16. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120.
17. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012;7:e37483.
18. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-764.
19. Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K. Cardiovascular comorbidities in hospitalised COPD patients: A determinant of future risk?. Eur Respir J 2015;46:846-849.
20. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One 2014;9:e85540.
21. Benson VS, Müllerová H, Vestbo J, Wedzicha JA, Patel A, Hurst JR; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Associations between gastrooesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med 2015;109:1147-1154.
22. Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2016;11:21-30.
23. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med 2014;35:157-163.
24. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-2234.
25. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003;361:449-456.
26. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: A pooled analysis. Respir Res 2011;12:161.
27. Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chron Obstruct Pulmon Dis 2016;11:193-205.
28. Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D. FLIGHT1 and FLIGHT2: Efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:1068-1079.
29. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209.
30. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators. LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015;10:1015-1026.
31. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
32. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: A phase 3 COPD study. Eur Respir J 2016;48:1030-1039.
33. Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. Respir Med 2016;112:65-74.
34. Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, Matera MG. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res 2016;17:70.
35. Spina D. Pharmacology of novel treatments for COPD: Are fixed dose combination LABA/LAMA synergistic?. Eur Clin Respir J 2015 [accessed 2017 May 3];2. Available from: Http://dx.doi.org/10.3402/ecrj.v2.26634
36. López-Campos JL. M(2)-b(2) interaction: A basis for combined bronchodilator treatment. Arch Bronconeumol 2013;49:279-281.
37. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, Roche N, Similowski T, Watz H, Worth H, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med 2015;109:785-802.
38. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: The role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-1357.
39. Foglio K, Carone M, Pagani M, Bianchi L, Jones PW, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 2000;94:256-263.
40. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217-227.
41. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-583.
42. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-597.
43. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26:420-428.
44. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180-184.
45. O'Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: Applying physiology to clinical practice. COPD Res and Practice 2015;1:4.
46. Washko GR, Fan VS, Ramsey SD, Mohsenifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, et al.; National Emphysema Treatment Trial Research Group. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;177:164-169.
47. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respir Med 2014;108:584-592.
48. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol (1985) 2006;101:1025-1035.
49. Rossi A, Khirani S, Cazzola M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008;3:521-529.
50. Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, Donaldson N, Polkey MI, Moxham J. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004;59:471-476.
51. Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-228.
52. HoshinoM, Ohtawa J, Akitsu K. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015;30:128-133.
53. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010;104:1288-1296.
54. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison. Thorax 2012;67:781-788.
55. Sanguinetti CM. The lungs need to be deflated: Effects of glycopyrronium on lung hyperinflation in COPD patients. Multidiscip Respir Med 2014;9:19.
56. Kostikas K, Siafakas NM. Does the term "deflators" reflect more accurately the beneficial effects of long-acting bronchodilators in COPD?. COPD 2016;13:537-539.
57. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150-159.
58. Garcia CS, Prota LF, Morales MM, Romero PV, Zin WA, Rocco PR. Understanding the mechanisms of lung mechanical stress. Braz J Med Biol Res 2006;39:697-706.
59. Vestbo J, Prescott E, Lange P; Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-1535.
60. Pistelli R, Lange P, Miller DL. Determinants of prognosis of COPD in the elderly: Mucus hypersecretion, infections, cardiovascular comorbidity. Eur Respir J Suppl 2003;40:10s-14s.
61. Siddiqi A, Berim I, Nabi H, Berenson CS, Sethi S. Association of impaired mucociliary clearance with occurrence of exacerbations in COPD. Am J Respir Crit Care Med 2009;179:A5350.
62. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: Insights from small airway pathology. Am J Respir Crit Care Med 2007;176: 454-459.
63. Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis 2014;5:85-98.
64. Martin C, Frija-Masson J, Burgel PR. Targeting mucus hypersecretion: new therapeutic opportunities for COPD?. Drugs 2014;74: 1073-1089.
65. Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, Wedzicha JA. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-478.
66. Cortijo J, Mata M, Milara J, Donet E, Gavaldà A, Miralpeix M, Morcillo EJ. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur Respir J 2011;37:244-254.
67. Tagaya E, Yagi O, Sato A, Arimura K, Takeyama K, Kondo M, Tamaoki J. Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD. Pulm Pharmacol Ther 2016;39:81-84.
68. Yaghi A, Zaman A, Cox G, Dolovich MB. Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects. Respir Med 2012;106:1139-1147.
69. Ghosh A, Boucher RC, Tarran R. Airway hydration and COPD. Cell Mol Life Sci 2015;72:3637-3652.
70. Meyer T, Reitmeir P, Brand P, Herpich C, Sommerer K, Schulze A, Scheuch G, Newman S. Effects of formoterol and tiotropiumbromide on mucus clearance in patients with COPD. Respir Med 2011;105:900-906.
71. Bennett WD, Almond MA, Zeman KL, Johnson JG, Donohue JF. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther 2006;19:96-100.
72. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, et al.; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013;42:636-646.
73. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: A study of the general population. Am J Respir Crit Care Med 2012; 186:975-981.
74. Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin DP, Hansel NN, Wise RA. Chronic productive cough is associated with death in smokers with early COPD. COPD 2014;11: 451-458.
75. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012;185:1218-1224.
76. Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Solanes-García I, Agüero R, Feu-Collado N, et al.; COPD History Assessment in Spain (CHAIN) Cohort. Differential effect of modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest 2015;148:159-168.
77. Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: The BLAZE study. Eur Respir J 2014;43:1599-1609.
78. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45:969-979.
79. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting b-agonist/long-acting muscarinic antagonist combinations in COPD: A network meta-analysis. Thorax 2016;71:15-25.
80. Kessler R, PartridgeMR, MiravitllesM, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: A pan-European cross-sectional study. Eur Respir J 2011;37:264-272.
81. van den Berge M, Hop WC, van der Molen T, van Noord JA, Creemers JP, Schreurs AJ, Wouters EF, Postma DS; COSMIC (COPD and Seretide: A Multi-Center Intervention and Characterization) study group. Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res 2012;13:44.
82. Donaldson GC, Seemungal TA, Hurst JR, Wedzicha JA. Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. Eur Respir J 2012;40:1123-1129.
83. Donohue JF, Jones P, Bartels C, Marvel J, D'Andrea P, Banerji D, Patalano F, Fogel R. Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD. Eur Respir J 2015;46:PA1013.
84. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1395-1399.
85. Cordoni PK, Berton DC, Squassoni SD, Scuarcialupi ME, Neder JA, Fiss E. Dynamic hyperinflation during treadmill exercise testing in patients with moderate to severe COPD. J Bras Pneumol 2012;38: 13-23.
86. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
87. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86-94.
88. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1:345-351.
89. Lorton D, Bellinger DL. Molecular mechanisms underlying b-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int J Mol Sci 2015;16:5635-5665.
90. Dumasius V, Sznajder JI, Azzam ZS, Boja J, Mutlu GM, Maron MB, Factor P. beta(2)-adrenergic receptor overexpression increases alveolar fluid clearance and responsiveness to endogenous catecholamines in rats. Circ Res 2001;89:907-914.
91. Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: Roles in inflammation and remodeling. Trends Pharmacol Sci 2015; 36:164-171.
92. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005;60:1361-1369.
93. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006;26:219-233.
94. Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, Maarsingh H, Zaagsma J, Meurs H. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J 2011;38:789-796.
95. Suzaki I, Asano K, Shikama Y, Hamasaki T, Kanei A, Suzaki H. Suppression of IL-8 production from airway cells by tiotropium bromide in vitro. Int J Chron Obstruct Pulmon Dis 2011;6:439-448.
96. Vacca G, Randerath WJ, Gillissen A. Inhibition of granulocyte migration by tiotropium bromide. Respir Res 2011;12:24.
97. Profita M, Bonanno A, Montalbano AM, Albano GD, Riccobono L, Siena L, Ferraro M, Casarosa P, Pieper MP, Gjomarkaj M. b2 long-acting and anticholinergic drugs control TGF-b1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta 2012;1822:1079-1089.
98. Holownia A, Wielgat P, Stasiak-Barmuta A, Kwolek A, Jakubow P, Szepiel P, Chyczewska E, Braszko JJ, Mroz RM. Tregs and HLA-DR expression in sputum cells of COPD patients treated with tiotropium and formoterol. Adv Exp Med Biol 2015;839:7-12.
99. Santus P, Buccellati C, Centanni S, Fumagalli F, Busatto P, Blasi F, Sala A. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res 2012;66:343-348.
100. Iesato K, Tatsumi K, Saito K, Ogasawara T, Sakao S, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, et al. Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells. Respiration 2008;76:434-441.
101. Narayanan V, Panariti A, Zamzameer F, Dessalle K, Baglole CJ, Ludwig MS, Halayko AJ, Eidelman DH, Hamid Q. Anti-Inflammatory effects of combined indacaterol and glycopyrronium on lung structural cells. Am J Respir Crit Care Med 2015;191:A5734.
102. Wex E, Kollak I, Duechs MJ, Naline E, Wollin L, Devillier P. The longacting b2-adrenoceptor agonist olodaterol attenuates pulmonary inflammation. Br J Pharmacol 2015;172:3537-3547.
103. Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005;172:878-884.
104. Yamamoto H, Teramoto H, Uetani K, Igawa K, Shimizu E. Cyclic stretch upregulates interleukin-8 and transforming growth factorbeta1 production through a protein kinase C-dependent pathway in alveolar epithelial cells. Respirology 2002;7:103-109.
105. Park JA, Tschumperlin DJ. Chronic intermittent mechanical stress increases MUC5AC protein expression. Am J Respir Cell Mol Biol 2009;41:459-466.
106. Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011;364:2006-2015.
107. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, et al.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2009;151: 517-527.
108. Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 2016;150:320-328.
109. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
110. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3:435-442.
111. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-525.
112. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-598.
113. Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: A randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. Int J Chron Obstruct Pulmon Dis 2015;10: 2393-2404.
114. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007;146:545-555.
115. Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting b2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-973.
116. GlaxoSmithKline. GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler in COPD at ERS International Congress; 2016 [accessed 2016 Oct 15]. Available from: Http://us.gsk.com/en-us/media/press-releases/2016/gsk-presents-positive-results-fromphase-iii-fulfil-study-of-closed-triple-combination-therapy-ffumecviversus-symbicort-turbohaler-in-copd-at-ers-international-congress/
117. ClinicalTrials.gov. A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). NCT02164513. Updated 2016 [accessed 2016 Oct 15]. Available from: Https://clinicaltrials.gov/ct2/show/NCT02164513?term= umeclidinium1vilanterol1fluticasone&rank=8
118. ClinicalTrials.gov. 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro in COPD Patients (TRIBUTE). Updated 2016 [accessed 2016 Oct 15]. Available from: Https://clinicaltrials. gov/ct2/show/NCT02579850